Breaking News Instant updates and real-time market news.

MBIO

Mustang Bio

$2.89

-0.11 (-3.67%)

08:19
08/13/19
08/13
08:19
08/13/19
08:19

Mustang Bio announces $9.28M grant to fund Phase 1 trial of MB-103

Mustang Bio announced that City of Hope has received a $9.28M grant from the California Institute for Regenerative Medicine to fund an ongoing Phase 1 clinical trial of MB-103 for the treatment of HER2-positive breast cancer with brain metastases. City of Hope patents covering the HER2 CAR were licensed to Mustang Bio in 2017. The City of Hope research team led by Saul Priceman, Ph.D., assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation, along with the clinical lead Jana Portnow, M.D., Associate Clinical Professor in the Department of Medical Oncology & Therapeutics Research, will use the funds to support the Phase 1 trial. The trial is expected to enroll 21 patients at City of Hope. The trial's primary objective is to determine the safety and recommended Phase 2 dosing of intraventricular delivery of HER2-specific CAR T cells. Secondary objectives include assessing cerebrospinal fluid and peripheral blood for HER2-CAR T cell persistence and endogenous immune system activation, describing changes in cytokine levels in the CSF and peripheral blood and describing changes in circulating tumor cells in the CSF.

  • 04

    Sep

MBIO Mustang Bio
$2.89

-0.11 (-3.67%)

04/18/19
HCWC
04/18/19
NO CHANGE
HCWC
H.C. Wainwright says Fortress business model validated by Mustang data
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $11 price target on Fortress Biotech (FBIO), noting that Mustang Bio (MBIO), a Fortress Biotech Company, published positive data related to its Phase 1/2 trial in children with XSCID, also known as bubble boy disease, delivering "compelling safety and efficacy." Pantginis sees Fortress continuing "to participate in the shares' appreciation showing continued validation of its business model."
06/20/19
CANT
06/20/19
INITIATION
Target $7
CANT
Overweight
Mustang Bio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros initiated Mustang Bio with an Overweight and $7 price target.
06/21/19
CANT
06/21/19
INITIATION
Target $7
CANT
Overweight
Cantor starts Mustang Bio with Overweight rating, $7 price target
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Mustang Bio with an Overweight rating and $7 price target. The company's pipeline centers on various gene and cell therapies are partnered with leading academic foundations, Piros tells investors in a research note. The analyst believes this approach of in-licensing these assets "may lift initial risks for future clinical development."
08/13/19
HCWC
08/13/19
INITIATION
Target $7
HCWC
Buy
Mustang Bio initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started Mustang Bio with a Buy rating and $7 price target. The analyst believes Mustang has a high probability of clinical success and that its "strong" academic partnerships may lead to "high quality" clinical data and provide additional funding while decreasing potential shareholder dilution. These factors highlight a "valuation disconnect for investors currently looking for compelling opportunities in an overcrowded biotech arena," Pantginis tells investors in a research note.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.